Association of adiponectin and amino terminal proBNP in peripheral arterial disease

Clinica Chimica Acta

Volumn 377, Issue 1-2, 2007, Pages 192-197

  Dieplinger, Benjamin ^a   Poelz, Werner ^b   Haltmayer, Meinhard ^a   Mueller, Thomas ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b JOHANNES KEPLER UNIVERSITY LINZ   (Austria)

Author keywords

Adiponectin; Atherosclerosis; Natriuetic peptides; Peripheral vascular disease; Risk factors

Indexed keywords

ADIPONECTIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTERY DISEASE; ARTICLE; BLOOD; BODY MASS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SMOKING; STATISTICAL SIGNIFICANCE;

ADIPONECTIN; AGED; FEMALE; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PERIPHERAL VASCULAR DISEASES;

EID: 33845423546     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2006.09.022     Document Type: Article

References (30)

1. Weitz J.I., Byrne J., Clagett G.P., et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation 94 (1996) 3026-3049
2. Belch J.J., Topol E.J., Agnelli G., et al. Prevention of Atherothrombotic Disease Network. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med 163 (2003) 884-892
3. Hiatt W.R. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 344 (2001) 1608-1621
4. Criqui M.H., Denenberg J.O., Langer R.D., and Fronek A. The epidemiology of peripheral arterial disease: importance of identifying the population at risk. Vasc Med 2 (1997) 221-226
5. Blake G.J., and Ridker P.M. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med 252 (2002) 283-294
6. Matsuzawa Y. Adiponectin: identification, physiology and clinical relevance in metabolic and vascular disease. Atheroscler Suppl 6 (2005) 7-14
7. Shimada K., Miyazaki T., and Daida H. Adiponectin and atherosclerotic disease. Clin Chim Acta 344 (2004) 1-12
8. Goldstein B.J., and Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 89 (2004) 2563-2568
9. Dieplinger B., Poelz W., Haltmayer M., and Muller T. Hypoadiponectinemia is associated with symptomatic atherosclerotic peripheral arterial disease. Clin Chem Lab Med 44 (2006) 830-833
10. Pischon T., Girman C.J., Hotamisligil G.S., Rifai N., Hu F.B., and Rimm E.B. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291 (2004) 1730-1737
11. Cavusoglu E., Ruwende C., Chopra V., et al. Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain. Eur Heart J 27 (2006) 2300-2309
12. Pilz S, Mangge H, Wellnitz B, et al. Adionectin and mortality in patients undergoing coronary angiography. J Clin Endocrinol Metab in press [Electronic publication ahead of print, doi:10.1210/jc.2006-0836].
13. Kistorp C., Faber J., Galatius S., et al. Plasma Adiponectin, body mass index and mortality in patients with chronic heart failure. Circulation 112 (2005) 1756-1762
14. George J., Patal S.P., Wexler D., et al. Circulating adiponectin in patients with congestive heart failure. Heart 92 (2006) 1420-1424
15. McCullough P.A., Omland T., and Maisel A.S. B-type natriuretic peptides: a diagnostic breakthrough for clinicians. Rev Cardiovasc Med 4 (2003) 72-80
16. Mueller T., Marschon R., Dieplinger B., et al. Factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations are not associated with chronic limb ischemia: the Linz Peripheral Arterial Disease (LIPAD) study. J Vasc Surg 41 (2005) 808-815
17. Rutherford R.B., Baker J.D., Ernst C., et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 26 (1997) 517-538
18. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130 (1999) 461-470
19. Mueller T., Gegenhuber A., Dieplinger B., Poelz W., and Haltmayer M. Capability of B-type natriuretic peptide (BNP) and amino-terminal proBNP as indicators of cardiac structural disease in asymptomatic patients with systemic arterial hypertension. Clin Chem 51 (2005) 2245-2251
20. Sattar N., Wannamethee G., Sarwar N., et al. Adiponectin and coronary artery disease, a prospective study and meta-analysis. Circulation 114 (2006) 623-629
21. Iwashima Y., Horio T., Suzuki Y., et al. Adiponectin and inflammatory markers in peripheral arterial occlusive disease. Atherosclerosis 188 (2006) 384-390
22. Eynatten M., Hamann A., Twardella D., Nawroth P.P., Brenner H., and Rothenbacher D. Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia, and heart failure in patients with coronary artery disease. Clin Chem 52 (2006) 853-859
23. Leng G.C., Lee A.J., Fowkes F.G., et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol 25 (1996) 1172-1181
24. Richards A.M., Nicholls M.G., Yandle T.G., et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 97 (1998) 1921-1929
25. Zoccali C., Mallamaci F., Tripepi G., et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13 (2002) 134-141
26. Becker B., Kronenberg F., Kielstein J.T., et al. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol 16 (2005) 1091-1098
27. Shoji T., Shinohara K., Hatsuda S., et al. Altered relationship between body fat and plasma adiponectin in end-stage renal disease. Metabolism 54 (2005) 330-334
28. Baratta R., Amato S., Degano C., et al. Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies. J Clin Endocrinol Metab 89 (2004) 2665-2671
29. Yamauchi T., Kamon J., Minokoshi Y., et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8 (2002) 1288-1295
30. von Eynatten M., Schneider J.G., Humpert P.M., et al. Decreased plasma lipoprotein lipase in hypoadiponectinemia: an association independent of systemic inflammation and insulin resistance. Diabetes Care 27 (2004) 2925-2929